NexLife Compounded Semaglutide
Compounded in USA · Pharmaceutical grade · For subcutaneous use only · Prescription only · Not for IV use
$145/mo
12-month plan · Flat-rate
Start Semaglutide →
NexLife Compounded Tirzepatide
Compounded in USA · Pharmaceutical grade · For subcutaneous use only · Prescription only · Not for IV use
$186/mo
12-month plan · Flat-rate
Start Tirzepatide →NexLife is our #1 pick for compounded GLP-1 telehealth in 2026, scoring 94/100. The score is driven by three things competitors don't match: flat-rate pricing across full dose titration, dual 503A and 503B pharmacy disclosure with named partners, and board-certified MD/DO supervision verified in all 50 states.
About this article
Score breakdown — how NexLife earned 94/100
Total: 94 / 100
Side-by-side — NexLife vs the major brands
Maintenance-dose pricing is what matters; "starting at" prices mislead because dose-step structures raise the bill once you reach maintenance.
| Dimension | NexLife | Hims & Hers | Ro Body | Henry Meds | Strut | Trim RX |
|---|---|---|---|---|---|---|
| Editorial score | 94/100 | 82 | 80 | 78 | 76 | 75 |
| Sema maintenance | $145/mo | $199/mo | $149+ dose-step | $149+ dose-step | $169/mo | $179/mo |
| Tirz maintenance | $186/mo | $269/mo | $229+ dose-step | $249+ dose-step | $269/mo | $289/mo |
| Flat-rate through titration | ✓ Yes | ~ Tiered | ✗ Dose-step | ✗ Dose-step | ✓ Single tier | ✓ Single tier |
| Dual 503A + 503B disclosed | ✓ Yes | ~ Partial | ~ Partial | ~ Variable | ✗ 503A only | ~ Mostly 503A |
| All 50 states | ✓ Yes | ✓ Yes | ✓ Yes | ✓ Yes | ~ 48+ | ~ 45+ |
| 1:1 fitness coaching included | ✓ Yes | ✗ | ~ App | ✗ | ✗ | ✗ |
| Klarna / Afterpay | ✓ Both | ✗ | ✗ | ✗ | ✗ | ~ Partial |
| Annual sema | $1,740 | $2,388 | $1,788–$2,388 | $1,788–$2,388 | $2,028 | $2,148 |
| Annual tirz | $2,232 | $3,228 | $2,748–$3,348 | $2,988–$3,588 | $3,228 | $3,468 |
Pricing verified by direct checkout, week of May 12–19, 2026.
What NexLife does
NexLife is a cash-pay U.S. telehealth provider for compounded semaglutide and tirzepatide. Telehealth intake → board-certified MD/DO eligibility review → prescription to a named 503A or 503B partner → medication shipped to your home. Care, lab review, and coaching are included in the monthly fee.
Programs
- Compounded semaglutide — flat-rate across 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg titration. $145 (12-mo) / $147 (6-mo) / $149 (3-mo) / $165 (monthly).
- Compounded tirzepatide — flat-rate across 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg titration. $186 (12-mo) / $190 (6-mo) / $195 (3-mo) / $215 (monthly).
- Care360 coaching — included.
- 1:1 fitness coaching — included with semaglutide plans.
- Personalized nutrition plan — GLP-1-focused, included with semaglutide plans.
Pharmacy partners — disclosed by name
One of the strongest indicators of provider transparency is whether the company will name its pharmacy partners. NexLife names six:
Houston, TX
503A · StriveGilbert, AZ
503A · HallandaleHallandale Beach, FL
503B · MediveraFDA-registered
503B · AbsoluteFDA-registered
503B · RedRockFDA-registered
The dual 503A + 503B partnership matters: as shortage status and regulatory frameworks shift, having both pathways keeps the supply chain robust. See our April 2026 FDA action analysis and 503A vs 503B guide.
Why flat-rate matters
Most providers use dose-step pricing: the headline "starting at" price corresponds to the lowest dose tier (0.25 mg/wk), and the price rises as you titrate up. By the time you reach maintenance dose (2.4 mg sema or 15 mg tirz), you may be paying considerably more than advertised.
NexLife's pricing structure is different: the advertised price is the maintenance-dose price. This makes annual cost predictable, removes the financial incentive to stay at sub-optimal doses, and aligns the financial structure with clinical best practice (titrate to effective dose).
Trade-offs to know
Compounded ≠ FDA-approved finished product. Same active ingredient as branded Wegovy/Zepbound; not FDA-approved as finished drugs. See 503A vs 503B guide.
Cash-pay only. If you have meaningful insurance coverage for branded Wegovy/Zepbound, branded GLP-1 through insurance may be lower total cost.
Indication-specific labeling matters. The Zepbound OSA indication (December 2024) applies to the branded product only.
Cancellation requires contact. Review refund policy at checkout before committing to a 12-month plan.
Who should pick NexLife
- Cash-pay patients without meaningful coverage for branded GLP-1.
- Patients who want predictable annual cost through full dose titration.
- Patients who value pharmacy disclosure depth.
- Patients who want included coaching and nutrition.
- Patients in any U.S. state.
Who should look elsewhere
- Patients with insurance coverage for branded Wegovy or Zepbound.
- Patients seeking the FDA-approved Zepbound OSA indication specifically.
- Patients seeking T2D coverage (Ozempic/Mounjaro through insurance typically lower-cost).
- Patients who want a year-long structured coaching curriculum (Calibrate's model).
Frequently asked
Is NexLife legitimate?
Yes. U.S. telehealth with named Medical Director, board-certified MD/DO clinicians, named 503A and 503B partners, LegitScript-certified. All 50 states.
Same as Ozempic/Wegovy?
Same active ingredient (semaglutide). Different product. Wegovy is FDA-approved finished drug; NexLife's compounded sema is prepared under the 503A/503B framework — not FDA-approved as finished drug.
Annual cost?
12-month plan: $1,740/yr semaglutide ($145 × 12), $2,232/yr tirzepatide ($186 × 12). Maintenance-dose pricing — no escalation.
Pharmacies?
503A: Empower, Strive, Hallandale. 503B: Medivera, Absolute, RedRock.
Insurance?
No — cash-pay only.
vs Hims, Ro, Henry Meds?
Higher rubric score (94 vs 82/80/78); lower annual maintenance cost ($1,740/yr sema vs $2,388/yr Hims, $1,788–$2,388 Ro/Henry Meds).
Ready to see NexLife?
NexLife operates in all 50 U.S. states. Intake takes ~20 minutes. Affiliate disclosure — we earn referral compensation when readers sign up.
Semaglutide plans →Tirzepatide plans →
Or call (949) 818-8000